Subscribe

login / sign up

close and back to page

Abbott to Acquire Cephea Valve Technologies, Inc.

Acquisition to further bolster Abbott's leading position in therapies for mitral valve disease, the most common type of heart valve ailment.

Abbott has announced that it has exercised its option to purchase Cephea Valve Technologies, Inc., a privately held medical device company developing a less-invasive heart valve replacement technology for people with mitral valve disease. Financial terms were not disclosed. Abbott provided capital and secured an option to purchase Cephea in 2015.

Read More Show Less

Abbott: A Healthy Outlook for the New Year

Abbott CFO highlights promising product pipeline and sustainable growth at key investor conference.

Originally Published by Abbott.

Each year brings resolutions; For Abbott, a new year means it is ready to keep delivering on its promises for better health through its life-changing technologies and translating that success into another year of outstanding performance.

Read More Show Less

Abbott: Blood Donations Needed

The need for life-saving blood can increase during the winter months, right when donations lag.

Originally Published by Abbott.

'Tis the season of giving. But, this time of year, most of us are so busy giving socks, sweaters and the latest video games that we don't think to give the gift that could save lives.

Read More Show Less

Abbott: Ending the AIDS Epidemic is Within Reach

At the height of the AIDS crisis in the 1980s, it was hard to imagine ending the AIDS epidemic.

Originally Published by Abbott.

As we approach the 30th anniversary of World AIDS Day, on December 1, we celebrate the tremendous progress made, and focus on working together to banish this epidemic to the history books.

Shooting for the Goal

While there is not a cure for HIV, we have made significant progress in testing and treating the virus, plus monitoring how people are responding to treatment – moving us closer to ending the epidemic. Today, three out of four people living with HIV know their status, a vital first step to getting treatment. And thanks to sustained access to antiretroviral therapy (ART), people with HIV are living longer and healthier lives.

As we work together to continue the fight against this global epidemic, goals have been set to reach specific targets so that AIDS is no longer a threat to our public health. To meet these targets, experts from the Joint United Nations Program on HIV/AIDS (UNAIDS) established the 90-90-90 plan to step up the HIV response so that by 2020:

  • 90 percent of all people living with HIV will know their HIV status
  • 90 percent of all people with diagnosed HIV infection will receive sustained ART
  • 90 percent of all people receiving ART will have viral suppression

To make these goals a reality, the global health community must accelerate efforts for people to get tested, putting outreach programs in place that meet the needs in different parts of the world.

Testing is Key

For more than 30 years, Abbott has helped in the fight against HIV and AIDS. We're especially proud of our scientists who worked nonstop to develop the first HIV blood test, approved by the U.S. FDA in 1985, and of our team of Virus Hunters who relentlessly search the globe for signs of new strains of the virus.

Abbott's broad range of tests span the entire continuum of care for people at risk for HIV or living with the virus whether they are getting treatment at a public health clinic in Chicago or living in a remote village in Uganda. Abbott's tests are also used to screen more than 60 percent of the world's blood supply, helping keep it safe from infectious diseases.

While significant progress has been made, one challenge in reaching the 90-90-90 goals is making testing technology accessible to everyone, including people living in remote areas. Outside of the U.S., Abbott is helping address this issue with the collection of a few drops of dried blood on a special paper. These samples can be transported without immediate refrigeration for testing, making it possible for clinicians to monitor their patients' HIV treatment response.

An additional gap that needs to be addressed is diagnosing HIV in infants, for whom time is of the essence because nearly half of HIV-positive babies who don't receive timely treatment die before they reach the age of two. Outside of the U.S., Abbott is tackling this challenge by providing an early infant diagnosis test that offers same-day results at the point of care. Mothers often travel many miles to bring their babies for a doctor's visit, so being able to provide same-visit results enables faster access to HIV treatment.

We Could Make It Happen

No one organization can end the AIDS epidemic on its own. Over the years, Abbott has established several partnerships to increase access to testing to key populations.

The global health community has the tools and technology to help create a future in which AIDS is no longer a threat to our public health. But it's going to take all of us working together, using all the tools at our disposal, to do so. On World AIDS Day and every day, let's do our part to put an end to this epidemic. Talk to your doctor and encourage others to get tested for HIV.

Abbott: Cybersecurity in the Connected Hospital

New white paper shares perceptions of medical device cybersecurity, need for collaboration to address cyber challenges.

Originally Published by Abbott.

In today's digital world, the rise of connected health – advanced, technology-enabled tools that provide people and their physicians with information to better manage their health – is transforming patient care. Studies have shown that connected devices can significantly improve patient outcomes by reducing hospitalizations and the overall cost of care.

Read More Show Less

Abbott: Top Internship for Healthcare and Tech

Interns have spoken: Abbott is the top college internship program for healthcare and tech & engineering.

Originally Published by Abbott.

Abbott recognizes the need to develop its future leaders early, and has been named the top healthcare and tech & engineering internship program by Vault.

Read More Show Less

Scientists Name Abbott a Top Workplace

The results are in: Abbott's a top 20 workplace for scientists.

Originally Published by Abbott.

What do scientists at Abbott do?

They create tiny, life-saving devices for baby's hearts, seek out neurons that cause Parkinson's and develop tests for Zika. They invent wearable sensors that eliminate the need for painful fingerpricks for people with diabetes. They drive breakthroughs in infant formula and make it possible to test half the world's blood supply.

They are our superheroes. And today, they've named us one of theirs.

After Science Magazine surveyed scientists at biotech companies around the world – ranking each on 23 characteristics from financial strength to having a research-driven environment – Abbott has landed for the 15th year on its Top Employers list.

The Brighton Consulting Group independently evaluated each company's employer reputation score, considering factors such as whether it treats its employees with respect and whether its work-culture values align with employees' personal values.

One of the coolest things about being a scientist at Abbott is we have tracks for both management – and science. You can continue to climb while never giving up the research you love, or you can choose to take a management track and lead a team. There are paths for advancement for both.

Last year alone, we launched more than 20 life-changing technologies around the globe. We do work that matters.

New Study Shows Abbott's Novel Diagnostic Test Could Help Rule Out Heart Attacks Earlier

Preliminary research indicates that a diagnostic test currently in development, that is done at the patient's side in minutes, has similar accuracy to a high-sensitive troponin test for early rule out of a heart attack .

Originally Published by Abbott.

For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether someone is having a heart attack. New data, published online in JAMA Cardiology, found a new blood test under development that is done right at the patient's side in as little as 15 minutes could identify nearly three-fifths (56.7 percent) of people at low-risk of experiencing a heart attack, similar to the results of a High Sensitive Troponin-I blood test done in the laboratory setting.

Read More Show Less

Abbott: Partnering for a Healthier Future

Abbott supports the First Ladies of Africa in the fight to end AIDS in children and keep mothers healthy.

Originally Published by Abbott.

In countries around the world, Abbott is working across its businesses and in partnerships with others to create healthier futures for families. One example: since 2014, Abbott's diagnostics business has supported the work of the Organization of African First Ladies Against HIV/AIDS (OAFLA – pictured above) to fight the AIDS epidemic in Africa, particularly among pregnant women and children – who are among the most vulnerable populations impacted by the disease.

At an OAFLA meeting on the sidelines of the UN General Assembly in New York City, Abbott and several other organizations are being recognized by OAFLA for longstanding partnership and support, including public-private partnerships that bring together technical, financial and other resources to focus on a global health challenge such as HIV/AIDS.

Read More Show Less

Abbott Named Global Industry Leader In Sustainability

Company achieves more than double the overall average industry score and maintains top industry scores in economic and social performance.

For the sixth consecutive year, Abbott (NYSE: ABT) has been named the leading company in its industry by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate sustainability and responsibility. As the industry leader in Health Care Equipment & Supplies, Abbott is one of the 60 companies recognized for leading their respective global industries.

Read More Show Less

NEW COVERAGE DECISION EXTENDS ABBOTT'S INNOVATIVE PAIN THERAPY OPTION TO 22 MILLION AMERICANS LIVING WITH CHRONIC PAIN

Abbott is the only company in the world with FDA and CE Mark approval to offer dorsal root ganglion (DRG) neurostimulation therapy to treat complex nerve pain conditions.

Originally Published by Abbott.

Abbott announced a new national coverage determination for the company's dorsal root ganglion (DRG) neurostimulation pain therapy through Aetna®, a leading health benefits company in the United States. With this coverage decision, Aetna will provide more than 22 million medical plan members with access to Abbott's DRG therapy for people with chronic pain.

Read More Show Less

Abbott: DRG Stimulator, A Life Changing Technology for Chronic Pain.

The new technological DRG therapy may be the key to easing daily tasks for those with chronic pain.

Originally Published by Abbott.

Living with chronic pain affects not just your body but also your mind. It can make getting around and getting along equally difficult.

But with innovation in health technology comes hope. Abbott has developed a new device found to be more effective than traditional therapy at relieving chronic pain.

Read More Show Less
© Copyright 2018 — DiversityInc All Rights Reserved.